Newborn Screening for CAH-Challenges and Opportunities

Natasha L Heather; Anna Nordenstrom

doi:10.3390/ijns7010011

Newborn Screening for CAH-Challenges and Opportunities

Int J Neonatal Screen. 2021 Feb 13;7(1):11. doi: 10.3390/ijns7010011.

Authors

Natasha L Heather^{1

2}, Anna Nordenstrom^{3

4

5}

Affiliations

¹ National Newborn Metabolic Screening programme, Specialist Chemical Pathology, LabPlus, Auckland City Hospital, Auckland 1023, New Zealand.
² Clinical Research Unit, Liggins Institute, University of Auckland, Auckland 1010, New Zealand.
³ Centre for Inherited Metabolic Diseases, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.
⁴ Department of Women's and Children's Health, Karolinska Institutet, SE-171 76 Stockholm, Sweden.
⁵ Pediatric Endocrinology Unit, Astrid Lindgren´s Children's Hospital, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.

Abstract

Newborn screening for congenital adrenal hyperplasia (CAH) using 17-hydroxyprogesterone (17-OHP) as an indicator of disease was first introduced in the 1970s [...].

Publication types

Editorial